References
- Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pul-monary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286–291.
- Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemc-itabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535–1540.
- Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821–1826.
- Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pan-creas cancer. Ann Oncol 1996; 7: 347–353.
- Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 1996; 78: 633–638.
- Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101–105.
- Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731–2736.
- Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 19;86: 1530–1533.
- Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89–93.
- Rini BI, Vogelzang NJ, Dumas MC, Wade JL, III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemc-itabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18: 2419–2426.
- De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37: 491–495.
- De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capil-lary leak syndrome. Ann Oncol 2001; 12: 1651–1652.
- Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16: 3426–3432.
- Assaly R, Olson D, Hammersley J, et al. Initial evi-dence of endothelial cell apoptosis as a mechanism of sys-temic capillary leak syndrome. Chest 2001; 120: 1301–1308.
- Rafi AQ, Zeytun A, Bradley MJ, et al. Evidence for the involvement of Fas ligand and perform n in the induction of vas-cular leak syndrome. J Immunol 1998; 161: 3077–3086.
- Chang AE, Rosenberg SA. Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol 1989; 5: 385–390.
- Railan D, Fivenson DP, Wittenberg G. Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J Am Acad Dermatol 2000; 43: 323–324.
- Marx G, Vangerow B, Burczyk C, et al. Evaluation of noninvasive determinants for capillary leakage syndrome in septic shock patients. Intensive Care Med 2000; 26: 1252–1258.
- Vander Els NJ, Miller V. Successful treatment of gemc-itabine toxicity with a brief course of oral corticosteroid thera-py. Chest 1998; 114: 1779–1781.
- Temper° MA, Brand R. Fatal pulmonary toxicity result-ing from treatment with gemcitabine. Cancer 1998; 82: 1800–1801.